Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 17Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neuroblastoma 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Renal Cell 4Burkitt Lymphoma 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2

Interventions

Nivolumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Radiotherapy 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mitomycin 1Ipilimumab 1Fluorouracil 1Colonoscopy 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Anal Canal Carcinoma × Ipilimumab × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡